Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment

Breast Cancer Research and Treatment

Volumn 138, Issue 1, 2013, Pages 225-233

  Calip, Gregory S ^a   Boudreau, Denise M ^a,b   Loggers, Elizabeth T ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Breast neoplasm; Comorbidity; Dyslipidemias; HMG CoA reductase inhibitors; Medication adherence

Indexed keywords

ANTINEOPLASTIC AGENT; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVOR; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONVALESCENCE; DRUG USE; DYSLIPIDEMIA; EARLY CANCER; FEMALE; HUMAN; LIFE EVENT; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 84874665077     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2424-2     Document Type: Article

References (40)

1. Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371-374. doi: 10.1200/JOP.2011.000460
2. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3
3. Marchioli R, Marfisi RM, Carinci F, Tognoni G (1996) Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease. Arch Intern Med 156(11):1158-1172
4. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322(24):1700-1707. doi: 10.1056/NEJM199006143222403
5. Pedersen TR, Kjekshus J, Berg K, Hughfelt T, Fargeman O, Thorgeirsson G, Pyorala K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383-1389
6. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA (2005) Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 62(14):1468-1475. doi: 10.2146/ajhp040419
7. Vinker S, Shani M, Baevsky T, Elhayany A (2008) Adherence with statins over 8 years in a usual care setting. Am J Manag Care 14(6):388-392
8. Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 223-239
9. Washington State Department of Health, Center for Health Statistics. Death Data. http://www.doh.wa.gov/ehsphl/CHS/chs-data/death/deatmain.htm. Accessed 15 June 2011
10. Bryson CL, Au DH, Young B, McDonell MB, Fihn SD (2007) A refill adherence algorithm for multiple short intervals to estimate refill compliance (ReComp). Med Care 45(6):497-504. doi: 10.1097/MLR.0b013e3180329368
11. Andrade SE, Kahler KH, Frech F, Chan KA (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15(8):565-574; discussion 575-567. doi: 10.1002/pds.1230
12. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25):3143-3421
13. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613-619
14. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update. CA Cancer J Clin 56(3):168-183
15. Danaei G, Tavakkoli M, Hernan MA (2012) Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 175(4):250-262. doi: 10.1093/aje/kwr301
16. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257):425-430. doi: 10.1038/343425a0
17. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS (2008) Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 155(4):772-779. doi: 10.1016/j.ahj.2007.12.011
18. Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 297(2):177-186. doi: 10.1001/jama.297.2.177
19. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459-478. doi: 10.1007/s10549-012-2114-5
20. Hewitt ME, Ganz P, Institute of Medicine (U.S.), American Society of Clinical Oncology (2006) From cancer patient to cancer survivor: lost in transition. National Academies Press, Washington, DC
21. Underwood JM, Townsend JS, Stewart SL, Buchannan N, Ekwueme DU, Hawkins NA, Li J, Peaker B, Pollack LA, Richards TB, Rim SH, Rohan EA, Sabatino SA, Smith JL, Tai E, Townsend GA, White A, Fairley TL, Division of Cancer Prevention and Control NCfCDP and Health Promotion, CfDC and Prevention (2012) Surveillance of demographic characteristics and health behaviors among adult cancer survivors - Behavioral Risk Factor Surveillance System, United States, 2009. MMWR Surveill Summ 61(1):1-23
22. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M, Muggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710-717
23. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, Jones A (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337. doi: 10.1186/1471-2407-10-337
24. Telli ML, Hunt SA, Carlson RW, Guardino AE (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25(23):3525-3533. doi: 10.1200/JCO.2007.11.0106
25. Telli ML, Witteles RM (2011) Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 9(2):243-249
26. Poluzzi E, Strahinja P, Lanzoni M, Vargiu A, Silvani MC, Motola D, Gaddi A, Vaccheri A, Montanaro N (2008) Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 64(4):425-432. doi: 10.1007/s00228-007-0428-8
27. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, van Wijk BL, Cadarette SM, Canning CF, Solomon DH (2007) Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med 167(8):847-852. doi: 10.1001/archinte.167.8.847
28. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM (2004) Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19(6):638-645. doi: 10.1111/j.1525-1497.2004.30516.x
29. Jackevicius CA, Mamdani M, Tu JV (2002) Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288(4):462-467
30. Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, Lambe M (2012) Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat 135(1):281-289. doi: 10.1007/s10549-012-2176-4
31. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5(12):930-942. doi: 10.1038/nrc1751
32. Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4):508-519. doi: 10.1038/sj.leu.2402476
33. Mannello F, Tonti GA (2009) Statins and breast cancer: may matrix metalloproteinase be the missing link. Cancer Invest 27(4):466-470. doi: 10.1080/07357900802491444
34. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9(1):10-19
35. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139-1148
36. Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29(9):585-593. doi: 10.3109/07357907.2011.616252
37. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461-1468. doi: 10.1093/jnci/djr291
38. Buist DS, LaCroix AZ, Brenneman SK, Abbott T III (2004) A population-based osteoporosis screening program: who does not participate, and what are the consequences? J Am Geriatr Soc 52(7):1130-1137. doi: 10.1111/j.1532-5415.2004.52311.x
39. Boudreau DM, Doescher MP, Jackson JE, Fishman PA, Saver BG (2004) Impact of healthcare delivery system on where HMO-enrolled seniors purchase medications. Ann Pharmacother 38(7-8):1317-1318. doi: 10.1345/aph.1D569
40. Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119(23):3028-3035. doi: 10.1161/CIRCULATIONAHA.108.768986